Amplia gets nod for new cancer drug trial ahead of US push

The Sydney Morning Herald - Nov 19, 2026

Amplia Therapeutics has received ethics approval for its ACCENT-Mini pancreatic cancer trial, paving the way to test daily doses of its narmafotinib drug alongside chemotherapy.

Read full article
More News
Business Vantage Views

Business Vantage Views is a dedicated online news network that brings to you the latest state of business and finance so that you can make the best judgment on investment and future planning.